TNAX Biopharma Corporation is developing TNAX101A, a humanized anti-DNAM-1 (CD226) monoclonal antibody for the treatment of idiopathic pulmonary disease (IPF) and inflammatory bowel disease (IBD). TNAX101A is a one-of-a-kind “single molecule” anti-fibrotic/inflammatory therapeutic mAb, which acts in a pleiotropic, synergistical and rippled way. It inhibits both innate and adaptive immunities. TNAX101A deactivates effector T cell functions, potentiates regulatory T cell functions and suppresses various pro-fibrotic/inflammatory cytokines/factors.
Our anti-DNAM-1 mAb demonstrates anti-fibrotic/inflammatory effects in various mouse models including bleomycin-induced IPF model, anti-CD40 mAb-induced IBD model and T-cell transfer IBD model. Unlike existing therapeutics, our anti-DNAM-1 mAb has a low risk of serious infections because it does not cause over-immunosuppression.
Pharmacological data indicate that other potential indications of TNAX101A are acute kidney injury (AKI), rheumatoid arthritis (RA), etc.
A second project is an anti-CD300a mAb, which is an efferocytosis stimulant. Our mAb promotes recovery from injury induced by cerebral and kidney ischemia.